Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2019-09-02 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension
Regulatory Filings Classification · 95% confidence The document is a press release titled "Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension." It details clinical trial progress, regulatory interactions (FDA feedback), and future plans, which is characteristic of an announcement intended for investors and the public regarding operational and clinical milestones. This type of announcement, which is not a formal financial report (like 10-K or IR) or a transcript, most closely aligns with a general regulatory/investor announcement. Since it is not a formal financial filing, and it is not a specific announcement like a dividend (DIV) or management change (MANG), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for miscellaneous corporate announcements, or potentially an Investor Presentation (IP) if it were structured as slides, but here it reads like a news release. Given the content focuses on clinical trial updates and FDA feedback, RNS is the most appropriate general classification for this type of corporate news release that doesn't fit a more specific operational category.
2019-09-02 English
Quantum Genomics Selected to Enter the European Rising Tech Label
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Quantum Genomics has been selected to enter the 'European Rising Tech label' on Euronext markets. This is a corporate announcement regarding company recognition and visibility, not a mandatory financial filing like a 10-K, an earnings release (ER), or a specific regulatory report (AR, IR, etc.). It is a general corporate update that doesn't fit the specific definitions for AGM-R, MANG, DIRS, CAP, DIV, etc. Given the options, the most appropriate general category for a non-standard, non-financial regulatory or corporate announcement that doesn't fit elsewhere is 'Regulatory Filings' (RNS), which serves as a broad category for miscellaneous official announcements.
2019-07-03 English
Quantum Genomics reçoit le label European Rising Tech
Governance Information Classification · 99% confidence The document is a press release announcing that Quantum Genomics has received the 'European Rising Tech' label from Euronext. It details the significance of this label, includes a quote from the CEO, and provides a brief 'About Us' section. This type of announcement, which communicates a specific corporate event, award, or general business update that doesn't fit neatly into standard financial reports (like 10-K, ER, or IR), is best classified as a general Regulatory Filing or Announcement. Since it is not a formal financial report, a dividend notice, a management change, or a transaction report, the most appropriate fallback category is Regulatory Filings (RNS). The document length (4156 chars) is short, but it is an announcement of an event, not an announcement *about* a report, so RPA is less suitable than RNS for general news.
2019-07-03 French
Bilan semestriel du contrat de liquidité au 30 juin 2019
Capital/Financing Update Classification · 99% confidence The document is titled "Bilan semestriel du contrat de liquidité au 30 juin 2019" (Semi-annual balance sheet of the liquidity contract as of June 30, 2019). It details the status and transactions (purchases and sales of shares) related to a liquidity contract over the first semester. This type of report, focusing on the management of the company's own shares under a specific agreement (liquidity contract), aligns most closely with the definition of 'Transaction in Own Shares' (POS), which covers share repurchase/issuance activities. Although it is a semi-annual report, it is highly specific to share transactions rather than a general financial performance report (like IR or 10-K). It is not a general earnings release (ER) or a comprehensive interim report (IR), but a specific regulatory disclosure regarding treasury stock management.
2019-07-02 French
Quantum Genomics Announces Result of Annual General Meeting
AGM Information Classification · 99% confidence The document explicitly announces the 'Result of Annual General Meeting' held on June 27. It details that all proposed resolutions were passed and mentions subsequent changes to the Board of Directors (resignation and appointment). This content directly relates to the proceedings and outcomes of the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document is not a short announcement linking to a report, but rather the summary of the meeting's results itself.
2019-06-27 English
Compte-rendu d'Assemblée générale et Gouvernance
AGM Information Classification · 99% confidence The document is titled "Compte-rendu d'Assemblée générale & Gouvernance" (General Meeting Report & Governance) and explicitly states that the Annual General Meeting (Assemblée générale annuelle) was held, resolutions were adopted, and voting results are implied. It also mentions the approval of a new Director's nomination and the resignation of another. This content strongly aligns with the purpose of an AGM report, which covers meeting proceedings, governance changes, and voting outcomes. The closest specific code is AGM-R (AGM Information). Although it mentions governance changes (MANG/CGR), the primary context is the meeting itself. It is not a DEF 14A (Remuneration) or DVA (Declaration of Voting Results), but rather the report/summary of the meeting where these things occurred.
2019-06-27 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.